Nao Taguchi

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Results of three multicenter observational studies of regimens containing tenofovir alafenamide among people with HIV in Japan.

Results of three multicenter observational studies of regimens containing tenofovir alafenamide among people with HIV in Japan.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: February 16, 2026

Medical Consultation and HIV Testing After AI-Based Symptom Check: Retrospective Cohort Study.

Medical Consultation and HIV Testing After AI-Based Symptom Check: Retrospective Cohort Study.

Journal: Journal of medical Internet research

Published: December 25, 2025

Twenty-four month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort.

Twenty-four month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: October 06, 2025

Association of concomitant pill burden with antiretroviral adherence and persistence: retrospective analysis of a Japanese claims database.

Association of concomitant pill burden with antiretroviral adherence and persistence: retrospective analysis of a Japanese claims database.

Journal: BMC infectious diseases

Published: February 07, 2025

Stigma Attitudes Toward HIV/AIDS From 2011 Through 2023 in Japan: Retrospective Study in Japan.

Stigma Attitudes Toward HIV/AIDS From 2011 Through 2023 in Japan: Retrospective Study in Japan.

Journal: Journal of medical Internet research

Published: December 05, 2024

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.

Journal: PloS one

Published: July 08, 2024

Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan.

Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: June 13, 2024

Treatment pattern and clinical outcomes of remdesivir in hospitalized COVID-19 patients with severe chronic kidney disease: a database analysis of acute care hospitals in Japan.

Treatment pattern and clinical outcomes of remdesivir in hospitalized COVID-19 patients with severe chronic kidney disease: a database analysis of acute care hospitals in Japan.

Journal: Clinical and experimental nephrology

Published: June 10, 2024

Prevalence and clinical characteristics of people with HIV with limited treatment options in Japan: A Japanese claims data analysis.

Prevalence and clinical characteristics of people with HIV with limited treatment options in Japan: A Japanese claims data analysis.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: January 28, 2024

Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis.

Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis.

Journal: Scientific reports

Published: December 22, 2023

The safety and effectiveness of remdesivir in a postmarketing surveillance study in Japan.

The safety and effectiveness of remdesivir in a postmarketing surveillance study in Japan.

Journal: Respiratory investigation

Published: September 27, 2023

Showing 1-11 of 11

Last Updated: 09/26/2026